• Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use
  • Members
  • Sign in
Westfair Communications
  • HOME
    • WESTCHESTER
    • FAIRFIELD
  • E-EDITIONS
    • Business Journal
    • Podcasts
  • MEMBERS
  • BUSINESS LISTS
  • INDUSTRIES
    • Real Estate
    • Economic Development
    • Hudson Valley
    • Courts
    • Banking & Finance
    • Construction
    • Economy
    • Education
    • Health Care
    • Food & Beverage
    • Government
    • Mergers & Acquisitions
    • Nonprofits
    • Retail
    • Technology
    • Home & Design
    • Health & Fitness
    • Travel
    • Lifestyle
  • SMALL BUSINESS
    • Small Business
    • Food & Restaurants
  • EVENTS
    • 2025 Real Estate
    • 2025 40 Under Forty
    • 2025 Women Innovators
    • 2025 C-Suite Awards
    • 2025 Doctors of Distinction
    • 2025 Hispanic Business Leaders
    • Events Calendar
    • Past Events
      • 2025
        • 2025 Women in Power
        • 2025 Millennial & Gen Z
      • 2024
        • 2024 Doctors of Distinction
        • 2024 Women Innovators
        • 2024 40 Under 40
        • 2024 Real Estate
        • 2024 Women In Power
      • 2023
        • 2023 Women In Power
        • Milli + Genz
        • Women Innovators
        • Forty Under 40
        • Doctors of Distinction
        • Real Estate
      • 2022
        • 2022 Millennial + GenZ Awards
        • 2022 C-Suite Awards
        • 2022 Doctors of Distinction
        • 2022 THE FUTURE OF REAL ESTATE
        • 2022 FORTY UNDER 40
      • 2021
        • 2021 FORTY UNDER 40 VIRTUAL EVENT
        • 2021 TOP WEALTH ADVISORS Virtual Event
        • 2021 Milli + GenZ Awards
        • 2021 C-SUITE
        • 2021 DOCTORS OF DISTINCTION
  • GOOD THINGS
  • VIDEOS
    • Our Starting Lineup
    • News Videos
  • PARTNERS
  • ADVERTISE
  • SUBSCRIBEACT NOW
    • NEWSLETTERS
    • DIGITAL ACCESS
No Result
View All Result
  • HOME
    • WESTCHESTER
    • FAIRFIELD
  • E-EDITIONS
    • Business Journal
    • Podcasts
  • MEMBERS
  • BUSINESS LISTS
  • INDUSTRIES
    • Real Estate
    • Economic Development
    • Hudson Valley
    • Courts
    • Banking & Finance
    • Construction
    • Economy
    • Education
    • Health Care
    • Food & Beverage
    • Government
    • Mergers & Acquisitions
    • Nonprofits
    • Retail
    • Technology
    • Home & Design
    • Health & Fitness
    • Travel
    • Lifestyle
  • SMALL BUSINESS
    • Small Business
    • Food & Restaurants
  • EVENTS
    • 2025 Real Estate
    • 2025 40 Under Forty
    • 2025 Women Innovators
    • 2025 C-Suite Awards
    • 2025 Doctors of Distinction
    • 2025 Hispanic Business Leaders
    • Events Calendar
    • Past Events
      • 2025
        • 2025 Women in Power
        • 2025 Millennial & Gen Z
      • 2024
        • 2024 Doctors of Distinction
        • 2024 Women Innovators
        • 2024 40 Under 40
        • 2024 Real Estate
        • 2024 Women In Power
      • 2023
        • 2023 Women In Power
        • Milli + Genz
        • Women Innovators
        • Forty Under 40
        • Doctors of Distinction
        • Real Estate
      • 2022
        • 2022 Millennial + GenZ Awards
        • 2022 C-Suite Awards
        • 2022 Doctors of Distinction
        • 2022 THE FUTURE OF REAL ESTATE
        • 2022 FORTY UNDER 40
      • 2021
        • 2021 FORTY UNDER 40 VIRTUAL EVENT
        • 2021 TOP WEALTH ADVISORS Virtual Event
        • 2021 Milli + GenZ Awards
        • 2021 C-SUITE
        • 2021 DOCTORS OF DISTINCTION
  • GOOD THINGS
  • VIDEOS
    • Our Starting Lineup
    • News Videos
  • PARTNERS
  • ADVERTISE
  • SUBSCRIBEACT NOW
    • NEWSLETTERS
    • DIGITAL ACCESS
No Result
View All Result
No Result
View All Result
Home Health Care

ContraFect’s CF-301 to enter phase one clinical trials

Leif Skodnick by Leif Skodnick
March 23, 2015
Reading Time: 1 min read
1
Share on FacebookShare on TwitterShare on LinkedIn
Order your reprint PDF today
Print Full Article

ContraFect Corp., a biotechnology company based in Yonkers developing therapeutic protein and antibody treatments for drug-resistant infectious diseases, announced that it will proceed to phase one clinical trials with its investigational new drug, CF-301, in the first quarter of 2015.

CF-301 will be tested as a treatment for drug-resistant Staph infections. It was licensed from The Rockefeller University and developed at ContraFect.

“We believe it has great potential to address the global crisis of drug-resistance,” ContraFect CEO Julia P. Gregory said in a statement. “CF-301, with its novel mechanism of action and full activity against drug-resistant bacteria and biofilms, is sorely needed to treat these life-threatening infections. We look forward to commencing the Phase 1 trial.”

According to a press release from ContraFect, there are approximately 120,000 cases annually of Staph bacteremia (a bloodstream infection) in the U.S. each year, causing approximately 30,000 deaths annually, and drug-resistant strains of Staph are now evolving and developing additional resistance against standard-of-care antibiotics, which may ultimately result in an increased number of cases and mortality from Staph bacteremia.

ContraFect made a $41.3 million initial public offering of securities over the summer. The company”™s common stock trades on the Nasdaq Capital Market, an exchange for corporations with small market capitalizations.

This page is available to subscribers. Click here to sign in or get access.

Previous Post

Turnaround Management Association hosts economic forum

Next Post

Brian Flaherty tapped to head CBIA’s policy arm

Leif Skodnick

Leif Skodnick

Leif Skodnick is a former reporter for Westfair Communications. He is a graduate of Columbia Journalism School, Mississippi College School of Law, and St. Lawrence University.

Related Posts

Owners of flood-prone Rye house sue developer for $1M
Construction

Owners of flood-prone Rye house sue developer for $1M

May 15, 2025
CLOTHES MAKE THE TEENS
Business Journals

CLOTHES MAKE THE TEENS

May 14, 2025
Arts & Leisure

ArtsWestchester launches campaign to counter $285,000 in federal cuts

May 14, 2025
Next Post

Brian Flaherty tapped to head CBIA's policy arm

Astorino, Day want to use bank settlement to fund new bridge

Brokers see shift to a landlord's market in 2015

Comments 1

  1. Pingback: ContraFect's CF-301 to enter phase one clinical trials - Westfair Online - PharmaLeaders.com

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Subscribe to our newsletter

Lifestyle

  • Exclusives
  • Good Things Happening
  • Food & Restaurants
  • Travel
  • Health & Fitness
  • Home & Design

World News

U.S. and world news for May 15
World News

U.S. and world news for May 15

by Peter Katz
May 15, 2025
0

Wholesale prices fall as Walmart warns of price increases The Producer Price Index, which tracks wholesale prices, fell 0.5% in...

CNN WIRE — Lawyers cleared AG Bondi memo on legality of Trump accepting 747 from Qatar

CNN WIRE — Lawyers cleared AG Bondi memo on legality of Trump accepting 747 from Qatar

May 14, 2025
U.S. and world news for May 14

U.S. and world news for May 14

May 14, 2025
Biden approves flood aid for Westchester

U.S. and world news for May 13

May 13, 2025
CNN WIRE — Harvard professors sue Trump

CNN WIRE — Behind the attacks on Harvard by the Trump Administration: VIDEO

May 12, 2025
U.S. and world news for May 12

U.S. and world news for May 12

May 12, 2025
No Result
View All Result

Latest News

Owners of flood-prone Rye house sue developer for $1M
Construction

Owners of flood-prone Rye house sue developer for $1M

by Bill Heltzel
May 15, 2025
0

The Lees claim they asked if there were any flooding issues and were told there had been...

U.S. and world news for May 15

U.S. and world news for May 15

May 15, 2025
CLOTHES MAKE THE TEENS

CLOTHES MAKE THE TEENS

May 14, 2025
U.S. Attorney to distribute $736K in DoorDash scam money

U.S. Attorney to distribute $736K in DoorDash scam money

May 14, 2025
ARKA’s Danbury Mission Technologies gets order for its laser system

ARKA’s Danbury Mission Technologies gets order for its laser system

May 14, 2025
Logo Westfair Business Journal

Latest News

Owners of flood-prone Rye house sue developer for $1M

U.S. and world news for May 15

CLOTHES MAKE THE TEENS

  • About Us
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use
  • Sign in

Trending Westchester

Subscribe to our newsletter

© 2024 Westfair Business Publications. All rights reserved. Westfair Communications (Westfair), a privately held publishing firm based in Mount Kisco, N.Y., publishes the Westchester County Business Journal in New York state and the Fairfield County Business Journal in Connecticut.

No Result
View All Result
  • HOME
    • WESTCHESTER
    • FAIRFIELD
  • E-EDITIONS
    • Business Journal
    • Podcasts
  • MEMBERS
  • BUSINESS LISTS
  • INDUSTRIES
    • Real Estate
    • Economic Development
    • Hudson Valley
    • Courts
    • Banking & Finance
    • Construction
    • Economy
    • Education
    • Health Care
    • Food & Beverage
    • Government
    • Mergers & Acquisitions
    • Nonprofits
    • Retail
    • Technology
    • Home & Design
    • Health & Fitness
    • Travel
    • Lifestyle
  • SMALL BUSINESS
    • Small Business
    • Food & Restaurants
  • EVENTS
    • 2025 Real Estate
    • 2025 40 Under Forty
    • 2025 Women Innovators
    • 2025 C-Suite Awards
    • 2025 Doctors of Distinction
    • 2025 Hispanic Business Leaders
    • Events Calendar
    • Past Events
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
  • GOOD THINGS
  • VIDEOS
    • Our Starting Lineup
    • News Videos
  • PARTNERS
  • ADVERTISE
  • SUBSCRIBE
    • NEWSLETTERS
    • DIGITAL ACCESS

© 2024 Westfair Business Journal. All rights reserved.

Notifications

  • My Account
  • Sign In
  • Subscribe
  • Sign Out